Internally developed products are forecasted to generate annual revenues of approximately $47 million with a projected EBITDA margin of approximately 20%.
Developer, manufacturer, and distributor of orthopaedic instruments, implants, and biomaterials.
The management team has identified products and services that are projected to generate annual revenues of approximately $47.0 million with a forecasted EBITDA margin of approximately 20% in the fifth year of commercialization (2023).